Industry Insight
Company News
Industry Insights

Home > News > Industry Insight > The Promise of Akk11’s Clinical Trial on Obesity Challenge((NCT06728098)

The Promise of Akk11’s Clinical Trial on Obesity Challenge((NCT06728098)

July 23 2025

The global health landscape is undergoing a significant transformation, marked by a dramatic increase in overweight and obesity rates. According to the World Health Organization (WHO), in 2025 this year, a staggering one in eight people worldwide were living with obesity.

In this context, scientific research is continuously exploring novel approaches to weight management and metabolic health. One such area of focus is the gut microbiome and its influence on human physiology. A promising development in this field is the ongoing clinical trial, "Akkermansia Muciniphila Akk11 Impact on Obesity and Metabolic Health" (NCT06728098).

This randomized, double-blinded, placebo-controlled study is designed to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in obese adults. Participants, aged 18-50 years with a BMI of 30 kg/m2 or higher, are receiving a daily Akkermansia muciniphila Akk11 capsule or a placebo for 84 days. The primary objective of the study is to assess the change in body weight from baseline to the end of the study period, with estimated completion in September 2025. This research holds potential to contribute to a deeper understanding of how specific probiotics might play a role in addressing the complex challenges of obesity.

No.999,Guangming Rd., Wujiang Economic and Technological Development Zone, Suzhou City, Jiangsu Province, China
Online Message
Leave a Message